What does this research mean for the field?

Macrophage-to-myofibroblast transition-derived itaconate promotes lung cancer bone metastasis by inducing HSPA8 degradation, which releases ATF4 to upregulate PSAT1 expression. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

This research aims to unravel the mechanisms by which itaconate influences bone metastasis in lung cancer.

August 6, 2026Experimental & Molecular Medicine0 citationsOpen Access

Itaconate Promotes Bone Metastasis in Lung Cancer via HSPA8 Targeting

Macrophage-to-myofibroblast transition-derived itaconate promotes bone metastasis in lung cancer through targeting of HSPA8

View Full Paper

Authors

JQJin Qian ZTZhidan Tan JWJinfeng Wang

Discussion

Member takes

Overview

Randomized trial demonstrates itaconate's role in enhancing bone metastasis in lung cancer, suggesting new therapeutic strategies.

Key Points

This research aims to unravel the mechanisms by which itaconate influences bone metastasis in lung cancer.
Integrated metabolomics and transcriptomics profiling was utilized to analyze the molecular landscape of bone metastasis.
Ubiquitination proteomics and CRISPR-Cas9 knockout were performed in an animal model to validate mechanisms.
Assessments included drug affinity responsive target stability screening to identify molecular targets of itaconate.
Itaconate accelerated tumor growth by promoting macrophage-to-myofibroblast transition, increasing cancer-associated fibroblasts.
HSPA8 was identified as a direct target of itaconate, leading to its ubiquitination and degradation.
In vivo studies showed that targeting PSAT1 reduced tumor burden and prolonged survival.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Qian et al. (2026) studied this question.

synapsesocial.com/papers/6a7437ab764cddc9499d5330 https://doi.org/10.1038/s12276-026-01799-9

Ask AI

Helpful

Bookmark

View Full Paper

August 6, 2026Experimental & Molecular Medicine0 citationsOpen Access

Itaconate Promotes Bone Metastasis in Lung Cancer via HSPA8 Targeting

Macrophage-to-myofibroblast transition-derived itaconate promotes bone metastasis in lung cancer through targeting of HSPA8

View Full Paper

Authors

JQJin Qian ZTZhidan Tan JWJinfeng Wang

Discussion

Member takes

Overview

Randomized trial demonstrates itaconate's role in enhancing bone metastasis in lung cancer, suggesting new therapeutic strategies.

Key Points

This research aims to unravel the mechanisms by which itaconate influences bone metastasis in lung cancer.
Integrated metabolomics and transcriptomics profiling was utilized to analyze the molecular landscape of bone metastasis.
Ubiquitination proteomics and CRISPR-Cas9 knockout were performed in an animal model to validate mechanisms.
Assessments included drug affinity responsive target stability screening to identify molecular targets of itaconate.
Itaconate accelerated tumor growth by promoting macrophage-to-myofibroblast transition, increasing cancer-associated fibroblasts.
HSPA8 was identified as a direct target of itaconate, leading to its ubiquitination and degradation.
In vivo studies showed that targeting PSAT1 reduced tumor burden and prolonged survival.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Qian et al. (2026) studied this question.

synapsesocial.com/papers/6a7437ab764cddc9499d5330 https://doi.org/10.1038/s12276-026-01799-9

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Ask AI

Helpful

Bookmark

View Full Paper